The increase was largely attributed to VYVGART’s performance, along with other products like ZEJULA and NUZYRA. Additionally, Zai Lab reported a net loss improvement, reflecting efforts in financial ...

Here is how Zai Lab Limited performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product Revenue- ZEJULA: $48.23 million versus ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for the third quarter of 2024, along with recent product highlights and corporate ...

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and ...

Zai Lab (NASDAQ:ZLAB) reported positive topline data from a Phase 3 study in China for KarXT in the treatment of schizophrenia. The FDA approved KarXT for schizophrenia in September. The drug will ...

Zai Lab (ZLAB) announced positive topline results from the company’s Phase 3 multi-center trial evaluating the safety and efficacy of KarXT or xanomeline and trospium chloride, in China ...

--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced positive topline results from the company’s Phase 3 multi-center trial evaluating the safety and efficacy of KarXT ...

Zai Lab Limited Unsponsored ADR (ZLAB) shares soared 14.7% in the last trading session to close at $33.18. The move was backed by solid volume with far more shares changing hands than in a normal ...

The Zai Restaurant menu features a delightful array of dishes, making it the perfect spot for brunch lovers. Each dish celebrates Argentinian flavour, showcasing the restaurant's commitment to quality ...